Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay (LU-NGS-2)
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Cancer Panel
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Princess Margaret Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years of age
- Pathologic or cytologic confirmation of lung adenocarcinoma (mixed adenocarcinoma and sarcomatoid features permitted)
- Stage IV disease
- Sufficient FFPE tumour tissue for OCCP testing
- Performance status 0-2
- Candidates for targeted therapy (TKIs) and/or clinical trials as determined by the patient's medical oncologist
- Prognosis > 6 months
- Known translocations of RET, MET exon14 skipping variants, or MET amplification are allowed
Exclusion Criteria:
● Patients with known EGFR, KRAS, BRAF and ERBB2 mutations or ALK or ROS1 fusions at study entry unless acquired resistance to molecularly targeted therapy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Stage IV Lung Adenocarcinoma
|
Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incremental actionable targets
Time Frame: 8-12 weeks from Oncomine Comprehensive Assay testing
|
Calculate the number of incremental actionable targets identified by the Oncomine Comprehensive Assay compared to current standard of care molecular profiling (EGFR, ALK) in patients with stage IV NSCLC.
|
8-12 weeks from Oncomine Comprehensive Assay testing
|
|
Number of clinical trial opportunities
Time Frame: 1 year from Oncomine Comprehensive Assay testing
|
Compile the number of clinical trial opportunities that patients with stage IV NSCLC would be eligible for based on targets identified by the Oncomine Comprehensive Assay compared to standard of care molecular profiling (EGFR, ALK).
|
1 year from Oncomine Comprehensive Assay testing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Test turnaround time
Time Frame: To be assessed after accruing 50 patients (up to 2.5 years) and after 100 patients (up to 5 years).
|
Calculate the time to receive Oncomine Comprehensive Assay results compared to the standard of care tissue molecular test turnaround time (EGFR, ALK).
|
To be assessed after accruing 50 patients (up to 2.5 years) and after 100 patients (up to 5 years).
|
|
Financial feasibility
Time Frame: To be assessed after accruing 50 patients (up to 2.5 years) and after 100 patients (up to 5 years).
|
Perform a cost consequence analysis to evaluate financial feasibility of the Oncomine Comprehensive Assay.
|
To be assessed after accruing 50 patients (up to 2.5 years) and after 100 patients (up to 5 years).
|
|
Patient willingness-to-pay
Time Frame: To be assessed after accruing 50 patients (up to 2.5 years) and after 100 patients (up to 5 years).
|
Evaluate patient willingness-to-pay for using a next generation sequencing assay, like the Oncomine Comprehensive Assay, using a validated patient survey.
|
To be assessed after accruing 50 patients (up to 2.5 years) and after 100 patients (up to 5 years).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-5638
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.